# Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

> **NCT04988607** · PHASE2 · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 90 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Bevacizumab
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT04988607
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08
- **Primary completion:** 2024-11
- **Final completion:** 2025-05
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04988607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04988607, "Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04988607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*